The effectiveness of plasma miR‑33a‑5p as a predictive biomarker for the efficacy of colorectal cancer chemotherapy

Sasaki,Megumi; Ishikawa,Toshiaki; Ishiguro,Megumi; Okazaki,Satoshi; Yamauchi,Shinichi; Kikuchi,Akifumi; Matsuyama,Takatoshi; Kawada,Kenro; Tokunaga,Masanori; Uetake,Hiroyuki; Kinugasa,Yusuke

doi:10.3892/ol.2021.12749

The effectiveness of plasma miR‑33a‑5p as a predictive biomarker for the efficacy of colorectal cancer chemotherapy

Authors:
- Megumi Sasaki
- Toshiaki Ishikawa
- Megumi Ishiguro
- Satoshi Okazaki
- Shinichi Yamauchi
- Akifumi Kikuchi
- Takatoshi Matsuyama
- Kenro Kawada
- Masanori Tokunaga
- Hiroyuki Uetake
- Yusuke Kinugasa
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, Graduate School, Tokyo Medical and Dental University, Bunkyo‑ku, Tokyo 113‑8519, Japan, Department of Specialized Surgeries, Graduate School, Tokyo Medical and Dental University, Bunkyo‑ku, Tokyo 113‑8519, Japan, Department of Translational Oncology, Graduate School, Tokyo Medical and Dental University, Bunkyo‑ku, Tokyo 113‑8519, Japan
Published online on: April 22, 2021 https://doi.org/10.3892/ol.2021.12749
Article Number: 489
Copyright: © Sasaki et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Several chemotherapeutic options are available for patients with metastatic colorectal cancer (mCRC), making it important to individualize treatment regimens. Individualization requires the clinical application of biomarkers for regimen selection, which is presently insufficient. miRNAs serve an important role in the control of biological processes in several types of cancer, acting as plasma biomarkers. The current study aimed to evaluate novel plasma microRNAs for predicting chemo‑resistance in chemotherapy for patients with colorectal cancer (CRC) by employing a Toray 3D‑Gene microRNA array‑based approach, which compared plasma content before and during treatment. Specific miRNAs that acted as biomarkers of the fluoropyrimidine (FP) + oxaliplatin (OX) + bevacizumab (BEV) regime, a common first‑line treatment for mCRC, were searched. The plasma samples of 110 patients with mCRC who had received the FP+OX+BEV regimen were subjected to microarray analyses using the 3D‑Gene miRNA microarray platform, after which miRNAs levels were quantified via reverse transcription‑ quantitative PCR. Patients exhibiting complete response, partial response (PR) and reduced stable disease (SD) were defined as responders. Patients with extended SD and progression disease (PD) were defined as non‑responders. Following microarray analysis, miR‑33a‑5p was selected as the candidate miRNA as it was upregulated in non‑responder plasma samples. The expression of miR‑33a‑5p was upregulated in the non‑responders (n=15) compared with the responders (n=95) (P=0.032). The high expression group demonstrated significantly poor progression‑free survival (P<0.01). To evaluate whether miR‑33a‑5p can serve as a marker of chemo‑resistance, miR‑33a‑5p expression levels were assessed at the following three time‑points: Pre‑point (before chemotherapy); PR‑point (3‑months after chemotherapy began); and PD‑point (the time at which recurrence or progression was recorded). The results revealed that expression levels were significantly increased at the PD‑point when compared with that at the pre‑point (P=0.024). The current study determined that the miR‑33a‑5p expression level in the plasma may serve as a predictive marker of efficacy and as a biomarker of chemo‑resistance.

View Figures

View References

1	Global Burden of Disease Cancer Collaboration. JAMA Oncol. 1:505–527. 2015.PubMed/NCBI
2	Schirripa M and Lenz HJ: Biomarker in CRC. Cancer J. 22:156–164. 2016. View Article : Google Scholar : PubMed/NCBI
3	Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, et al: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol. 15:1065–1075. 2014. View Article : Google Scholar : PubMed/NCBI
4	Yamazaki K, Nagase M, Tamagawa H, Ueda S, Tamura T, Murata K, Eguchi Nakajima T, Baba E, Tsuda M, Moriwaki T, et al: Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Ann Oncol. 27:1539–1546. 2016. View Article : Google Scholar : PubMed/NCBI
5	Gustavsson B, Carlsson G, Machover D, Petrelli N, Roth A, Schmoll HJ, Tveit KM and Gibson F: A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer. 14:1–10. 2015. View Article : Google Scholar : PubMed/NCBI
6	Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, et al: ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 27:1386–1422. 2016. View Article : Google Scholar : PubMed/NCBI
7	Kjersem JB, Ikdahl T, Lingjaerde OC, Guren T, Tveit KM and Kure EH: Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Mol Oncol. 8:59–67. 2014. View Article : Google Scholar : PubMed/NCBI
8	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
9	Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI
10	Wang S, Xiang J, Li Z, Lu S, Hu J, Gao X, Yu L, Wang L, Wang J, Wu Y, et al: A plasma microRNA panel for early detection of colorectal cancer. Int J Cancer. 136:152–161. 2015. View Article : Google Scholar : PubMed/NCBI
11	Rasmussen MH, Jensen NF, Tarpgaard LS, Qvortrup C, Rømer MU, Stenvang J, Hansen TP, Christensen LL, Lindebjerg J, Hansen F, et al: High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer. Mol Oncol. 7:637–646. 2013. View Article : Google Scholar : PubMed/NCBI
12	Li XW, Qiu SJ and Zhang X: Overexpression of miR-215-3p sensitizes colorectal cancer to 5-fluorouracil induced apoptosis through regulating CXCR1. Eur Rev Med Pharmacol Sci. 22:7240–7250. 2018.PubMed/NCBI
13	Fang L, Li H, Wang L, Hu J, Jin T, Wang J and Yang BB: MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression. Oncotarget. 5:2974–2987. 2014. View Article : Google Scholar : PubMed/NCBI
14	Zhou Y, Wan G, Spizzo R, Ivan C, Mathur R, Hu X, Ye X, Lu J, Fan F, Xia L, et al: miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. Mol Oncol. 8:83–92. 2014. View Article : Google Scholar : PubMed/NCBI
15	Chen Q, Xia HW, Ge XJ, Zhang YC, Tang QL and Bi F: Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases. Asian Pac J Cancer Prev. 14:7421–7426. 2013. View Article : Google Scholar : PubMed/NCBI
16	Shen Y, Zhou J, Li Y, Ye F, Wan X, Lu W, Xie X and Cheng X: miR-375 mediated acquired chemo-resistance in cervical cancer by facilitating EMT. PLoS One. 9:e1092992014. View Article : Google Scholar : PubMed/NCBI
17	Nishibeppu K, Komatsu S, Imamura T, Kiuchi J, Kishimoto T, Arita T, Kosuga T, Konishi H, Kubota T, Shiozaki A, et al: Plasma microRNA profiles: Identification of miR-1229-3p as a novel chemoresistant and prognostic biomarker in gastric cancer. Sci Rep. 10:31612020. View Article : Google Scholar : PubMed/NCBI
18	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
19	Komatsu S, Ichikawa D, Kawaguchi T, Takeshita H, Miyamae M, Ohashi T, Okajima W, Imamura T, Kiuchi J, Arita T, et al: Plasma microRNA profiles: Identification of miR-23a as a novel biomarker for chemoresistance in esophageal squamous cell carcinoma. Oncotarget. 7:62034–62048. 2016. View Article : Google Scholar : PubMed/NCBI
20	Konishi H, Ichikawa D, Komatsu S, Shiozaki A, Tsujiura M, Takeshita H, Morimura R, Nagata H, Arita T, Kawaguchi T, et al: Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma. Br J Cancer. 106:740–747. 2012. View Article : Google Scholar : PubMed/NCBI
21	Komatsu S, Ichikawa D, Hirajima S, Kawaguchi T, Miyamae M, Okajima W, Ohashi T, Arita T, Konishi H, Shiozaki A, et al: Plasma microRNA profiles: Identification of miR-25 as a novel diagnostic and monitoring biomarker in oesophageal squamous cell carcinoma. Br J Cancer. 111:1614–1624. 2014. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Wang SY, Shiboski S, Belair CD, Cooperberg MR, Simko JP, Stoppler H, Cowan J, Carroll PR and Blelloch R: miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance. PLoS One. 9:e985972014. View Article : Google Scholar : PubMed/NCBI
24	Sheng S, Xie L, Wu Y, Ding M, Zhang T and Wang X: MiR-144 inhibits growth and metastasis in colon cancer by down-regulating SMAD4. Biosci Rep. 39:392019. View Article : Google Scholar : PubMed/NCBI
25	Hu J, Ruan J, Liu X, Xiao C and Xiong J: MicroRNA-301a-3p suppressed the progression of hepatocellular carcinoma via targeting VGLL4. Pathol Res Pract. 214:2039–2045. 2018. View Article : Google Scholar : PubMed/NCBI
26	Zhu X, Ma SP, Yang D, Liu Y, Wang YP, Lin T, Li YX, Yang SH, Zhang WC and Wang XL: miR-142-3p suppresses cell growth by targeting CDK4 in colorectal Cancer. Cell Physiol Biochem. 51:1969–1981. 2018. View Article : Google Scholar : PubMed/NCBI
27	Jiang M, Xu B, Li X, Shang Y, Chu Y, Wang W, Chen D, Wu N, Hu S, Zhang S, et al: O-GlcNAcylation promotes colorectal cancer metastasis via the miR-101-O-GlcNAc/EZH2 regulatory feedback circuit. Oncogene. 38:301–316. 2019. View Article : Google Scholar : PubMed/NCBI
28	Cheng H, Xue J, Yang S, Chen Y, Wang Y, Zhu Y, Wang X, Kuang D, Ruan Q, Duan Y, et al: Co-targeting of IGF1R/mTOR pathway by miR-497 and miR-99a impairs hepatocellular carcinoma development. Oncotarget. 8:47984–47997. 2017. View Article : Google Scholar : PubMed/NCBI
29	Shen Y, Qi L, Li Y, Zhang Y, Gao X, Zhu Y and Wang K: The downregulation of lncRNA PGM5-AS1 inhibits the proliferation and metastasis via increasing miR-484 expression in colorectal cancer. Cancer Biother Radiopharm. 36:220–229. 2021. View Article : Google Scholar : PubMed/NCBI
30	Yang L, Men WL, Yan KM, Tie J, Nie YZ and Xiao HJ: MiR-340-5p is a potential prognostic indicator of colorectal cancer and modulates ANXA3. Eur Rev Med Pharmacol Sci. 22:4837–4845. 2018.PubMed/NCBI
31	Chang W, Zhang L, Xian Y and Yu Z: MicroRNA-33a promotes cell proliferation and inhibits apoptosis by targeting PPARα in human hepatocellular carcinoma. Exp Ther Med. 13:2507–2514. 2017. View Article : Google Scholar : PubMed/NCBI
32	Zhou Y, Huang Z, Wu S, Zang X, Liu M and Shi J: miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST. J Exp Clin Cancer Res. 33:122014. View Article : Google Scholar : PubMed/NCBI
33	Kim SH, Kim GJ, Umemura T, Lee SG and Cho KJ: Aberrant expression of plasma microRNA-33a in an atherosclerosis-risk group. Mol Biol Rep. 44:79–88. 2017. View Article : Google Scholar : PubMed/NCBI
34	Lefebvre P, Chinetti G, Fruchart JC and Staels B: Sorting out the roles of PPAR α in energy metabolism and vascular homeostasis. J Clin Invest. 116:571–580. 2006. View Article : Google Scholar : PubMed/NCBI
35	Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T and Gonzalez FJ: Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J Biol Chem. 273:5678–5684. 1998. View Article : Google Scholar : PubMed/NCBI
36	Panigrahy D, Kaipainen A, Huang S, Butterfield CE, Barnés CM, Fannon M, Laforme AM, Chaponis DM, Folkman J and Kieran MW: PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci USA. 105:985–990. 2008. View Article : Google Scholar : PubMed/NCBI
37	Zhang N, Chu ES, Zhang J, Li X, Liang Q, Chen J, Chen M, Teoh N, Farrell G, Sung JJ, et al: Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-κB signaling pathway. Oncotarget. 5:8330–8340. 2014. View Article : Google Scholar : PubMed/NCBI
38	Grau R, Punzón C, Fresno M and Iñiguez MA: Peroxisome-proliferator-activated receptor α agonists inhibit cyclo-oxygenase 2 and vascular endothelial growth factor transcriptional activation in human colorectal carcinoma cells via inhibition of activator protein-1. Biochem J. 395:81–88. 2006. View Article : Google Scholar : PubMed/NCBI
39	Lee G, Liang C, Park G, Jang C, Jung JU and Chung J: UVRAG is required for organ rotation by regulating Notch endocytosis in Drosophila. Dev Biol. 356:588–597. 2011. View Article : Google Scholar : PubMed/NCBI
40	Wang H, Sun T, Hu J, Zhang R, Rao Y, Wang S, Chen R, McLendon RE, Friedman AH, Keir ST, et al: miR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathways. J Clin Invest. 124:4489–4502. 2014. View Article : Google Scholar : PubMed/NCBI
41	Katoh M and Katoh M: Notch signaling in gastrointestinal tract (Review). Int J Oncol. 30:247–251. 2007.PubMed/NCBI
42	Meng RD, Shelton CC, Li Y-M, Qin LX, Notterman D, Paty PB and Schwartz GK: gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res. 69:573–582. 2009. View Article : Google Scholar : PubMed/NCBI
43	Zhao L, Zhang D, Ma H, Jin M, Huang F and Zhang T: High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: A meta-analysis. Panminerva Med. 58:48–58. 2016.PubMed/NCBI
44	Sun L, Ke J, He Z, Chen Z, Huang Q, Ai W, Wang G, Wei Y, Zou X, Zhang S, et al: HES1 promotes colorectal cancer cell resistance to 5 Fu by inducing of EMT and ABC transporter proteins. J Cancer. 8:2802–2808. 2017. View Article : Google Scholar : PubMed/NCBI
45	Zhou Y, Zang X, Huang Z and Zhang C: TWIST interacts with endothelin-1/endothelin A receptor signaling in osteosarcoma cell survival against cisplatin. Oncol Lett. 5:857–861. 2013. View Article : Google Scholar : PubMed/NCBI